Table S1. Oligonucleotides used in this study. Restriction sites are underlined.

Name	Sequence	Orient.
Cloning Primers		
RND RNAi f	CGGGATCCATGTTCAGGACTATAGGAATCG	sense
RND RNAi r	CCCAAGCTTTGCCTCCGTTATCACTGGTTTC	anti
RNDMHT f	CCCAAGCTTATGTTCAGGACTATAGGAATCGTG	sense
RNDMHT r	CGGGATCCATGTAAAGAATTTTCCCCCAAACG	anti
Mutagenesis Primers		
D80Afwd	CTCGCTCGATTGCTCTGGCCATCGAGGCTTTTTG	sense
D80Arev	CAAAAAGCCTCGATGGCCAGAGCAATCGAGCGAG	anti
RNase H target oligonucleotides		
9S H Target	ATTGGTGGGCAACAATACCT	anti
12S H Target	ACAAATCTGCTTTACAACGA	anti
3’ rRNA oligonucleotide probes		
9S 3’ Probe	ATAAATATATTAATTACTGCACGTTATT	anti
12S 3’ Probe	TCAATAATCAATCCTTGCGTACTTATA	anti
qRT-PCR primers		
9S fwd	AATGCTATTAGATGGGTGTGGAA	sense
9S rev	GCTGGCATCCATTTCTGACT	anti



Fig. S1. **Properties of the TbRND antibody.** Entire TbRND immunoblot in which the position of native TbRND is indicated with a black arrow and the recombinant protein is indicated with a grey arrow. Loaded are whole cell protein extracts from 8 x 10^6 cells collected from uninduced (-tet) and TbRND RNAi induced (+tet) cells, protein extract from Percoll-fractionated mitochondria using 8 x 10^7 cells as starting material, and 100 ng recombinant TbRND.